MX9200240A - Derivados de 1-2[amino-3,4-dioxo-1-ciclobuten-1il]amino]alquil]-acido, procedimiento para su preparacion y composicion farmaceutica que los contiene. - Google Patents

Derivados de 1-2[amino-3,4-dioxo-1-ciclobuten-1il]amino]alquil]-acido, procedimiento para su preparacion y composicion farmaceutica que los contiene.

Info

Publication number
MX9200240A
MX9200240A MX9200240A MX9200240A MX9200240A MX 9200240 A MX9200240 A MX 9200240A MX 9200240 A MX9200240 A MX 9200240A MX 9200240 A MX9200240 A MX 9200240A MX 9200240 A MX9200240 A MX 9200240A
Authority
MX
Mexico
Prior art keywords
carbon atoms
alkyl
amino
hydrogen
dioxo
Prior art date
Application number
MX9200240A
Other languages
English (en)
Spanish (es)
Inventor
William Alvin Kinney
Deanna Colette Garrison
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of MX9200240A publication Critical patent/MX9200240A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Lubricants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX9200240A 1991-01-22 1992-01-20 Derivados de 1-2[amino-3,4-dioxo-1-ciclobuten-1il]amino]alquil]-acido, procedimiento para su preparacion y composicion farmaceutica que los contiene. MX9200240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64415791A 1991-01-22 1991-01-22
US07/806,861 US5168103A (en) 1991-01-22 1991-12-17 [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives

Publications (1)

Publication Number Publication Date
MX9200240A true MX9200240A (es) 1994-03-31

Family

ID=27094416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9200240A MX9200240A (es) 1991-01-22 1992-01-20 Derivados de 1-2[amino-3,4-dioxo-1-ciclobuten-1il]amino]alquil]-acido, procedimiento para su preparacion y composicion farmaceutica que los contiene.

Country Status (22)

Country Link
US (2) US5168103A (OSRAM)
EP (1) EP0496561B1 (OSRAM)
JP (1) JP3167770B2 (OSRAM)
KR (1) KR100206055B1 (OSRAM)
AT (1) ATE119873T1 (OSRAM)
AU (1) AU639629B2 (OSRAM)
CA (1) CA2059704C (OSRAM)
CZ (1) CZ286407B6 (OSRAM)
DE (1) DE69201655T2 (OSRAM)
DK (1) DK0496561T3 (OSRAM)
ES (1) ES2071428T3 (OSRAM)
FI (1) FI105551B (OSRAM)
GR (1) GR3015456T3 (OSRAM)
HU (2) HU215838B (OSRAM)
IE (1) IE65873B1 (OSRAM)
IL (1) IL100679A (OSRAM)
MX (1) MX9200240A (OSRAM)
NZ (1) NZ241330A (OSRAM)
RU (1) RU2039035C1 (OSRAM)
SK (1) SK280268B6 (OSRAM)
TW (1) TW211564B (OSRAM)
UA (1) UA27741C2 (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
KR970002653B1 (ko) * 1993-12-16 1997-03-07 엘지전자 주식회사 냉장고
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
ATE229501T1 (de) * 1996-07-17 2002-12-15 Wyeth Corp Substituierte n-arylmethylamino-cyclobuten-3,4- dion-derivate
US5763474A (en) * 1996-07-17 1998-06-09 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5846999A (en) * 1996-07-17 1998-12-08 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5780505A (en) * 1996-07-17 1998-07-14 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones
US5750574A (en) * 1996-07-17 1998-05-12 American Home Products Corporation Fluorinated N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
NZ502509A (en) * 1997-08-01 2002-08-28 Wyeth Corp Process for the preparation of [2-((8,9)- dioxo-2,6-diazabicyclo[5.2.0]-non-1(7)-en-2-yl)-ethyl] phosphonic acid
JPH1177971A (ja) * 1997-09-05 1999-03-23 Shinano Kenshi Co Ltd ブランケット胴及び該ブランケット胴を備えたオフセット印刷装置
DE69936848T2 (de) * 1998-04-14 2008-05-15 The General Hospital Corp., Boston Verwendung von d-serin oder d-alanin zur behandlung von schizophrenie
US6376555B1 (en) 1998-12-04 2002-04-23 American Home Products Corporation 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
US6166050A (en) * 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
KR100565008B1 (ko) * 2000-02-01 2006-03-30 주식회사유한양행 4-하이드라지노-3-사이클로부텐-1,2-다이온 유도체 및이들의 제조 방법
KR100742086B1 (ko) * 2001-07-27 2007-07-23 주식회사유한양행 4-페닐-3-사이클로부텐-1,2-다이온 유도체 및 그의 제조방법
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
MXPA05010763A (es) * 2003-04-09 2005-12-12 Wyeth Corp Composiciones farmaceuticas para administracion intranasal de acido [2-(8, 9-dioxo-2, 6-diazabiciclo [5.2.0] non-1(7) -en-2-il) alquil- fosfonico] y metodos de uso del mismo.
PL1611144T3 (pl) * 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GT200400213A (es) * 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
CA2557301A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
MX2007004138A (es) 2004-10-08 2007-06-15 Wyeth Corp Derivados de acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il-) alquil] fosfonico y metodos de preparacionde los mismos.
MX2010002191A (es) * 2007-08-27 2010-03-17 Wyeth Llc Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
KR20110139274A (ko) 2009-03-19 2011-12-28 와이어쓰 엘엘씨 ［2-(8,9-다이옥소-2,6-다이아자바이사이클로［5.2.0］논-1(7)-엔-2-일)에틸］포스폰산 및 이의 전구체의 제조 방법
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3514158B1 (en) 2013-01-29 2022-10-12 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
CA2898774C (en) 2013-01-29 2021-07-13 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX378566B (es) 2016-05-19 2025-03-11 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
JP2019527233A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
KR102462288B1 (ko) 2016-08-01 2022-11-01 앱티닉스 인크. 스피로-락탐 및 비스-스피로-락탐 nmda 수용체 조정제 및 그의 용도
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
WO2018229744A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
AU2019215058A1 (en) 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518660A1 (de) * 1965-07-09 1969-08-14 Huels Chemische Werke Ag Verfahren zur Herstellung aminosubstituierter Dioxocyclobutene
GB1563090A (en) * 1975-07-31 1980-03-19 Smith Kline French Lab Cyclobutene-diones
US4390701A (en) * 1981-05-18 1983-06-28 Bristol-Myers Company 1-Amino-2-[3-(3-piperidinomethylphenoxy)propylamino]cyclobutene-3,4-dione
US4521625A (en) * 1982-10-02 1985-06-04 Smith Kline & French Laboratories Limited Dioxocyclobutene compounds
US4927970A (en) * 1987-05-14 1990-05-22 Bristol-Myers Company Substituted 3-cyclobutene-1,2-dione intermediates
US4902687A (en) * 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists

Also Published As

Publication number Publication date
HU9200192D0 (en) 1992-04-28
HUT61970A (en) 1993-03-29
UA27741C2 (uk) 2000-10-16
HK1005588A1 (en) 1999-01-15
FI920261A0 (fi) 1992-01-21
EP0496561B1 (en) 1995-03-15
GR3015456T3 (en) 1995-06-30
NZ241330A (en) 1993-10-26
FI920261L (fi) 1992-08-23
FI105551B (fi) 2000-09-15
JP3167770B2 (ja) 2001-05-21
CA2059704A1 (en) 1992-07-23
ES2071428T3 (es) 1995-06-16
SK280268B6 (sk) 1999-10-08
KR920014765A (ko) 1992-08-25
RU2039035C1 (ru) 1995-07-09
EP0496561A2 (en) 1992-07-29
EP0496561A3 (en) 1992-12-23
DE69201655D1 (de) 1995-04-20
AU639629B2 (en) 1993-07-29
JPH04321654A (ja) 1992-11-11
DK0496561T3 (da) 1995-05-22
IE65873B1 (en) 1995-11-29
ATE119873T1 (de) 1995-04-15
IL100679A (en) 1996-10-31
IL100679A0 (en) 1992-09-06
KR100206055B1 (ko) 1999-07-01
US5168103A (en) 1992-12-01
CA2059704C (en) 2002-07-16
CZ286407B6 (en) 2000-04-12
TW211564B (OSRAM) 1993-08-21
HU211653A9 (en) 1995-12-28
HU215838B (hu) 2000-06-28
US5240946A (en) 1993-08-31
AU1030192A (en) 1992-07-30
IE920176A1 (en) 1992-07-29
DE69201655T2 (de) 1995-07-13
CZ14492A3 (en) 1994-01-19
SK14492A3 (en) 1995-02-08

Similar Documents

Publication Publication Date Title
MX9200240A (es) Derivados de 1-2[amino-3,4-dioxo-1-ciclobuten-1il]amino]alquil]-acido, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ATE14579T1 (de) Pharmazeutische heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen.
ES8403858A1 (es) Procedimiento para la preparacion de dipeptidos carboxialquilicos.
PT83843B (pt) Processo para a preparacao de promedicamentos de rapamicina
ATE25251T1 (de) Anti srs-a carbonsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische formulierungen.
FR2662162B1 (fr) Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
MX9203239A (es) Derivados de 1-(dihidroxifenil)-2-amino-etanol y composiciones farmaceuticas que los contienen.
MX9207335A (es) Nuevos derivados del acido fosfonosuccinico, procesos para su preparacion y composicion farmaceuticas que los contiene.
ES2089497T3 (es) Derivados de 23-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que contienen estos derivados asi como su utilizacion como medicamentos.
YU2692A (sh) Novi derivati tetrazola i postupak za njihovo pripremanje
MX9301404A (es) Derivados de 2-oxoquinolina, procedimiento para su preparacion, preparado farmaceutico que los contiene y procedimiento para la obtencion de tal preparado farmaceutico.
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
AR036764A1 (es) Derivados de [[2-(amino-3,4-dioxo-1-ciclobuten-1-il)amino]alquil]-acido para el tratamiento del dolor
FR2623504B1 (fr) Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
ES8205224A1 (es) Un procedimiento para la preparacion de acidos 1-carbadetiapen-2-em-3-carboxilios 6-1-y 2-sustituidos.
MX9804017A (es) Compuestos pesticidas, composiciones y procedimientos para su preparacion.
ES8105715A1 (es) Procedimiento de preparar derivados isoquinolinicos
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
ES8504180A1 (es) Procedimiento para preparar nuevos derivados de piperidina
MX174093B (es) 1,1-DIOXIDOS DE 3,4-DIHIDRO-2-ALQUIL-3-OXO-N-ARIL-2H[1] BENZOTIENO[3,2-e]-1,2-TIAZINO-4-CARBOXIAMIDA
JPS6426554A (en) Novel derivative of 1-benzoyl-2-oxo-5-alkoxy pyrrolidine, manufacture, use as drug and composition
SE8903313L (sv) Nya 2-metoxikarbonyl-substituerade n,n'-di-(trimetoxibensoyl)-piperaziner, foerfarande foer framstaellning daerav och terapeutiska foereningar innehaallande dem
ES2060979T3 (es) Nuevos derivados de n-(23-vincristoil) y n-(5'-noranhidro-23-vinblastinoil) de acido 1-amino-metil-fosforico, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE266646T1 (de) Phenanthryl-piperazinyl-dicarbonsäure als selective nmda-rezeptor modulierende mittel
SE8204791D0 (sv) Process for preparing alkoxy-vincaminic acid esters and alkoxy-apovincaminic acid esters

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: CLARIANT PRODUKTE (DEUTSCHLAND) GMBH.*

MM Annulment or lapse due to non-payment of fees